![]() |
Tags | Domains | Searches | Statistics | Options | Advanced Search |
PharmaGazette - Jul 10, 2007
Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® …
Also tagged: abt, eu, abbott, drug regulations and approval, emea, as, humira, jia, jra
Know More Media - Health Care / Pharmaceutical / Fitness - May 8, 2007
Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® …
Also tagged: eu, abbott, drug regulations and approval, emea, as, humira
Know More Media - Health Care / Pharmaceutical / Fitness - Apr 5, 2007
Abbott (NYSE: ABT) has submitted a supplemental Biologics License Application (sBLA) to the USFDA and a Type II Variation to the EMEA, seeking marketing approval of HUMIRA® (adalimumab) as a treatment for moderate to …
Also tagged: abbott, autoimmune diseases, drug marketing, drug regulations and approval, as
Know More Media - Health Care / Pharmaceutical / Fitness - Mar 29, 2007
Co-developed by Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP), REMICADE® (infliximab) was first approved in the U.S. ( by the USFDA) in 1998 as treatment U.S. for adult Crohn's disease (CD) and later, in …
Also tagged: cd, uc, drug regulations and approval, emea, chmp, as, schering plough corporation
Know More Media - Health Care / Pharmaceutical / Fitness - Feb 28, 2007
The USFDA granted marketing approval to Abbott (NYSE: ABT) for HUMIRA® (adalimumab) with the following new indications: treatment for reducing the signs and symptoms and inducing and maintaining clinical remission in …
Also tagged: abbott, gi, antibodies, drug regulations and approval, crohn s